Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis

J Natl Cancer Inst. 2012 Dec 5;104(23):1837-40. doi: 10.1093/jnci/djs435. Epub 2012 Oct 23.

Abstract

Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Arteries
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects*
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Incidence
  • Neoplasms / drug therapy*
  • Randomized Controlled Trials as Topic
  • Risk
  • Thromboembolism / chemically induced*
  • Thromboembolism / epidemiology*

Substances

  • Antineoplastic Agents
  • Cisplatin